The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol

نویسنده

  • Dong-Ryeol Ryu
چکیده

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Xanthine oxidase inhibitory and antioxidant potential of Indian Muscodor species

Xanthine oxidase is a key enzyme responsible for hyperuricemia, a pre-disposing factor for Gout and oxidative stress-related diseases. Only two clinically approved xanthine oxidase inhibitors Allopurinol and Febuxostat are currently used for treatment of hyperuricemia. However, owing to their side effects there is a need for new non-purine-based selective inhibitors of xanthine oxidase. In the ...

متن کامل

Treatment of Gout — A new Approach Dr . Anil Batta

Since a long time back allopurinol has been constantly use to subsidize uric acid level in blood by competitive and suicidal inhibition of xanthine oxidase. Barring a few side few tolerable effects there was never felt any emergency for invention of an alternative. But a dire research was going on to bring into light an alternative which is better than allopurinol in some aspects. Now a non-pur...

متن کامل

Febuxostat: a new treatment for hyperuricaemia in gout.

Febuxostat is a new non-purine xanthine oxidase inhibitor that is more potent than allopurinol 300 mg daily. In two Phase III trials, significantly more febuxostat-treated gout patients met the primary endpoint [serum urate (sUA) <6 mg/dl (<360 mumol/l) at the last three visits] (48 and 53% with 80 mg; 65 and 62% with 120 mg), compared with those receiving allopurinol 300 mg (22 and 21%; P < 0....

متن کامل

Diabetes and gout: efficacy and safety of febuxostat and allopurinol

AIM Assess influences of demographics and co-morbidities of gout patients with or without diabetes on safety and efficacy of urate-lowering agents. METHODS Post-hoc analysis of 312 diabetic and 1957 non-diabetic gout patients [baseline serum urate levels (sUA) ≥8.0 mg/dl] enrolled in a 6-month randomized controlled trial comparing urate-lowering efficacy (ULE) and safety of daily xanthine oxi...

متن کامل

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout

INTRODUCTION Gout is a common and disabling cause of arthritis in middle-aged and elderly populations, with its main predisposing factor being hyperuricemia (serum urate > 6.8 mg/dL). Options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group of drugs known as uricosurics that stimulate the renal excretion of uric acid. A proportion of patient...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 36  شماره 

صفحات  -

تاریخ انتشار 2017